

## Press Release

17th of Dec 2021

### ISR ensures large-scale vaccine production via an agreement with Revitalife

ISR Vaccine AB has entered into an agreement, Memorandum of Understanding (MoU) with Revitalife Holding Limited for the production and sale of our inhalation vaccine for SARS-CoV2. The Memorandum of Understanding refers to the "fill and seal" of ISR's vaccines with licensing rights for production and sales in North Africa and the Middle East (MENA) with an annual capacity of at least 200 million doses.

*"We are very pleased that we are now securing a partner in MENA to be able to produce the vaccine for another large market. In order to reach out quickly after completion of clinical studies, it is important for us to carry out tech transfers and build production capacity for different territories in parallel,"* comments Ola Winqvist, CEO of ISR.

ISR has now secured large-scale GMP production of the components for the vaccine through the signed agreements with Northway and Oncovir. Formulated vaccine will then be sent to partners with licenses to package the vaccine in Iconovo's disposable inhaler. With today's agreement, we have cooperation with Bangladesh, Malaysia / Indonesia and now MENA, which means that we can quickly ensure capacity for production to the market

#### For further information, please contact:

Ola Winqvist

CEO, ISR Immune System Regulation Holding AB (publ)

E-post: [ola.winqvist@israb.se](mailto:ola.winqvist@israb.se)

Phone: +46 (0)70 5427939

#### About ISR Immune System Regulation Holding AB (publ)

*ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceuticals. Mangold is the company's Certified Adviser, and can be reached on phone +46 (0)8-463 80 00.*

[www.israb.se](http://www.israb.se)

*This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying with EU's Market Abuse Regulation (MAR), and the Market Abuse Act*